1. Introduction {#sec1-marinedrugs-14-00134}
===============

*Aspergillus* section *Fumigati* and its teleomorph *Neosartorya* include many important species because they can be pathogenic or allergenic to man, as well as causing food spoilage and producing mycotoxins. Certain species are also found to produce interesting bioactive secondary metabolites that can be considered to have potential for drug development \[[@B1-marinedrugs-14-00134]\]. For this reason, we have investigated the bioactive secondary metabolites produced from the cultures of four *Neosartorya* species collected from soil in Thailand, i.e., *Neosartorya glabra* KUFC 6311 \[[@B2-marinedrugs-14-00134]\], *N. pseudofischeri* KUFC 6422 \[[@B3-marinedrugs-14-00134]\], *N. siamensis* KUFC 6349 \[[@B4-marinedrugs-14-00134]\] and *N. fischeri* KUFC 6344 \[[@B5-marinedrugs-14-00134]\], as well as six marine-derived species of *Neosartorya*, including *N. paulistensis* KUFC 7898 \[[@B6-marinedrugs-14-00134]\], *N. laciniosa* KUFC 7896 \[[@B5-marinedrugs-14-00134]\], *N. spinosa* KUFC 8104, *N. tsunodae* KUFC 9213 \[[@B5-marinedrugs-14-00134]\], *N. siamensis* KUFA 0017 and *N. takakii* KUFC 7898 \[[@B7-marinedrugs-14-00134]\], as well as one marine-derived *Aspergillus* species (*Aspergillus similanensis* KUFA 0013) \[[@B8-marinedrugs-14-00134],[@B9-marinedrugs-14-00134]\]. Recently, we have also reported the antifungal activity of the crude extract of *N. quadricincta* KUFA 0064, isolated from an agricultural soil in Southern Thailand, against plant pathogenic fungi, which are causative agents of diseases of economically-important plants of Thailand \[[@B10-marinedrugs-14-00134]\]. So far, the only report on secondary metabolites of *N. quadricincta* was by Ozoe et al., who described the isolation of dihydroisocoumarin derivative, PF1223, from the culture of *N. quadricincta* strain PF1223 (unidentified source). This compound was shown to inhibit the \[^3^H\] EBOB binding by 65% \[[@B11-marinedrugs-14-00134]\]. Thus, in our ongoing search for bioactive secondary metabolites from marine-derived fungi from Thai waters, we have investigated the culture of *N. quadricincta* KUFA 0081, isolated from the marine sponge *Clathria reinwardti*, which was collected from the Coral reef at Samae San Island in the Gulf of Thailand. The ethyl acetate extract of the culture of this fungus yielded, besides the previously described 2,3-dihydro-6-hydroxy-2,2-dimethyl-4*H*-1-benzopyran-4-one (**4a**) \[[@B12-marinedrugs-14-00134]\], two new polyketide derivatives (**1**, **5**) and seven new benzoic acid derivatives (**2a**, **2b**, **3**, **4b**, **6a**, **6b** and **7**) ([Figure 1](#marinedrugs-14-00134-f001){ref-type="fig"}). All of the isolated compounds were tested for their antibacterial activity against Gram-positive and Gram-negative bacteria, as well as multidrug-resistant isolates from the environment and for their antifungal activity against yeast (*Candida albicans* ATCC 10231), filamentous fungus (*Aspergillus fumigatus* ATCC 46645) and dermatophyte (*Trichophyton rubrum* FF5). Additionally, these compounds were also evaluated for their in vitro growth inhibitory activity against the MCF-7 (breast adenocarcinoma), NCI-H460 (non-small cell lung cancer) and A375-C5 (melanoma) cell lines by the protein binding dye SRB method.

2. Results and Discussion {#sec2-marinedrugs-14-00134}
=========================

Compound **1** was isolated as white crystals (mp, 176--177 °C), and its molecular formula C~14~H~18~O~5~ was established on the basis of the (+)-HRESIMS *m/z* 267.1243 \[M + H\]^+^ (calculated 267.1332), indicating six degrees of unsaturation. The IR spectrum showed absorption bands for hydroxyl (3455 cm^−1^), conjugated ester carbonyl (1723 cm^−1^) and aromatic (1612, 1596 cm^−1^) groups. The ^13^C NMR, DEPT and HSQC spectra ([Table 1](#marinedrugs-14-00134-t001){ref-type="table"}, [Supplementary Information, Figures S2 and S4](#app1-marinedrugs-14-00134){ref-type="app"}) exhibited the signals of one conjugated ester carbonyl (δ~C~ 168.2), five quaternary sp^2^ (δ~C~ 164.6, 158.3, 152.8, 111.7, 105.5), one methine sp^2^ (δ~C~ 94.5), one oxygen bearing quaternary sp^3^ (δ~C~ 88.8), one oxygen bearing methine sp^3^ (δ~C~ 70.8), two methoxyl (δ~C~ 56.1 and 56.0) and three methyl (δ~C~ 21.5, 17.8 and 11.2) groups. The ^1^H NMR spectrum ([Table 1](#marinedrugs-14-00134-t001){ref-type="table"}, [Supplementary Information, Figure S1](#app1-marinedrugs-14-00134){ref-type="app"}) revealed the presence of, besides a singlet of one aromatic proton at δ~H~ 6.41, a quartet of the oxymethine proton at δ~H~ 4.22 (*J* = 6.4 Hz), two singlets of the methoxyl groups at δ~H~ 3.97 s and 3.92 s, two methyl singlets at δ~H~ 2.12 s and 1.76 s, a methyl doublet at δ~H~ 0.87 (*J* = 6.4 Hz) and a broad band of the hydroxyl proton at δ~H~ 2.15. The ^1^H and ^13^C data ([Table 1](#marinedrugs-14-00134-t001){ref-type="table"}) revealed the presence of a pentasubstituted benzene ring. That this pentasubstituted benzene ring was part of the 5,7-dimethoxy-3,4-dimethyl-2-benzofuran-1(3*H*)-one ring system was corroborated by the HMBC correlations ([Table 1](#marinedrugs-14-00134-t001){ref-type="table"}, [Figure 2](#marinedrugs-14-00134-f002){ref-type="fig"}a, [Supplementary Information, Figure S5](#app1-marinedrugs-14-00134){ref-type="app"}) of H-6 (δ~H~ 6.41, s) to C-7a (δ~C~ 105.3), C-4 (δ~C~ 111.7), C-7 (δ~C~ 158.3), C-5 (δ~C~ 164.6) and C-1 (δ~C~ 168.2), of OMe-5 (δ~H~ 3.92, s) to C-5, of OMe-7 (δ~H~ 3.97, s) to C-7, of H~3~-8 (δ~H~ 2.12, s) to C-4, C-3a (δ~C~ 152.8) and C-5, of H~3~-9 (δ~H~ 1.76, s) to C-3a and of the NOESY correlations of H-6 to OMe-5 and OMe-7. That another substituent of C-3 was a 1-hydroxyethyl group was supported by the COSY correlations of H-10 (δ~H~ 4.22, q, *J* = 6.4 Hz) to H~3~-11 (δ~H~ 0.87, d, *J* = 6.4 Hz), by the HMBC correlations of H~3~-9 to C-10 (δ~C~ 70.8), C-3 (δ~C~ 88.8) and C-3a and of H~3~-11 (δ~H~ 0.87, d, *J* = 6.4 Hz) to C-3 and C-10 ([Table 1](#marinedrugs-14-00134-t001){ref-type="table"}, [Figure 2](#marinedrugs-14-00134-f002){ref-type="fig"}a), as well as by the NOESY correlations of H~3~-8 to H-10, H~3~-9, of H~3~-11 to H-10, OH-10 and of H~3~-9 to H-10 ([Table 1](#marinedrugs-14-00134-t001){ref-type="table"}, [Figure 2](#marinedrugs-14-00134-f002){ref-type="fig"}b, [Supplementary Information, Figure S6](#app1-marinedrugs-14-00134){ref-type="app"}). Final proof of the structure and the stereochemistry assigned to compound **1** was provided by its X-ray analysis ([Figure 3](#marinedrugs-14-00134-f003){ref-type="fig"}), and since the diffraction data were collected with a Gemini PX Ultra equipped with CuKα radiation, it was possible to establish the absolute configurations of C-3 and C-10, respectively, as 3*R* and 10*S*. Since **1** is a new compound, we have named it quadricinctone A.

Compound **2a** was also isolated as white crystals (mp. 147--148 °C), and its molecular formula C~12~H~12~O~4~ was determined based on the (+)-HRESIMS *m/z* 221.0820 \[M + H\]^+^ (calculated 221.0814), indicating seven degrees of unsaturation. The IR spectrum showed absorption bands for hydroxyl (3447 cm^−1^), a conjugated carbonyl (1696 cm^−1^), aromatic (1609 cm^−1^) and olefin (1647 cm^−1^) groups. The ^13^C NMR, DEPT and HSQC spectra ([Table 2](#marinedrugs-14-00134-t002){ref-type="table"}, [Supplementary Information, Figures S8 and S10](#app1-marinedrugs-14-00134){ref-type="app"}) exhibited the signals of one conjugated carboxyl carbonyl (δ~C~ 167.0), three quaternary sp^2^ (δ~C~ 156.8, 123.0, 120.5), five methine sp^2^ (δ~C~ 130.8, 128.6, 127.9, 122.8, 115.7), one oxy-quaternary sp^3^ (δ~C~ 80.5), one oxymethylene sp^3^ (δ~C~ 67.1) and one methyl (δ~C~ 23.3) groups. The ^1^H NMR spectrum ([Table 2](#marinedrugs-14-00134-t002){ref-type="table"}, [Supplementary Information, Figures S7](#app1-marinedrugs-14-00134){ref-type="app"}) revealed, besides the presence of three aromatic protons of the 1,2,4 trisubstituted benzene ring at δ~H~ 6.79, d (*J* = 8.4 Hz), 7.65, d (*J* = 2.1 Hz) and 7.69, dd (*J* = 8.4, 2.1 Hz), two doublets of the protons of a *cis*-double bond at δ~H~ 6.56, d (*J* = 10.0 Hz) and 5.74, d (*J* = 10.0 Hz), a methyl singlet at δ~H~ 1.31, a singlet of two protons at δ~H~ 3.46 and two broad signals of the hydroxyl protons at δ~H~ 12.59 and 5.07, respectively. The COSY spectrum ([Table 2](#marinedrugs-14-00134-t002){ref-type="table"}, [Figure 4](#marinedrugs-14-00134-f004){ref-type="fig"}a, [Supplementary Information, Figures S9](#app1-marinedrugs-14-00134){ref-type="app"}) exhibited cross-peaks of H-4 (δ~H~ 6.56, d, *J* = 10.0 Hz) to H-3 (δ~H~ 5.74, d, *J* = 10.0 Hz), of H-7 (δ~H~ 7.69, dd, *J* = 8.4, 2.1 Hz) to H-5 (δ~H~ 7.65, d, *J* = 2.1 Hz) and H-8 (δ~H~ 6.79, d, *J* = 8.4 Hz), confirming the presence of the 1,2,4 trisubstituted benzene ring and the *cis*-double bond. That the 1,2,4-trisubsituted benzene ring and the *cis*-double bond were part of the 2*H*-chromene-6-carboxylic acid moiety was corroborated by the HMBC correlations ([Figure 4](#marinedrugs-14-00134-f004){ref-type="fig"}a, [Supplementary Information, Figures S11](#app1-marinedrugs-14-00134){ref-type="app"}) of H-5 to C-4 (δ~C~ 122.8), C-7 (δ~C~ 130.8), C-8a (δ~C~ 156.8) and C-11 (δ~C~ 167.0), of H-7 to C-5 (δ~C~ 127.9), C-8a, C-11, of H-8 to C-4a (δ~C~ 120.5), C-6 (δ~C~ 123.0) and C-8a, as well as of H-3 to C-4a and of H-4 to C-4a, C-5 and C-8a. As the HMBC spectrum also exhibited correlations of the methyl singlet at δ~H~ 1.31 (H~3~-9) to C-3, C-2 (δ~C~ 80.5) and C-10 (δ~C~ 67.1) and of the singlet at δ~H~ 3.46 (H-10) to C-2, C-3 and CH~3~-9 (δ~C~ 23.3), the methyl and hydroxymethyl groups were placed on C-2. The NOESY correlations ([Figure 4](#marinedrugs-14-00134-f004){ref-type="fig"}b, [Supplementary Information, Figures S12](#app1-marinedrugs-14-00134){ref-type="app"}) of H-4 to H-3 and H-5, of H-3 to H-4, H~3~-9 and H~2~-10, of H-8 to H-7, H~2~-10 and H~3~-9 and of H~3~-9 to H-8, H-10 also confirmed this hypothesis. Since compound **2a** was obtained in a suitable crystal, X-ray analysis was carried out, and the ORTEP view shown in [Figure 5](#marinedrugs-14-00134-f005){ref-type="fig"} revealed that the absolute configuration of C-2 is *S*. A literature search indicated that **2a** has never been previously reported; therefore, it was named quadricinctapyran A.

Compound **2b** was isolated as a white solid (mp. 118--119 °C), and its molecular formula C~14~H~14~O~5~ was established on the basis of the (+)-HRESIMS *m/z* 263.0971 \[M + H\]^+^ (calculated 263.0919), indicating eight degrees of unsaturation. The ^1^H and ^13^C NMR spectral features ([Supplementary Information, Figures S13 and S14](#app1-marinedrugs-14-00134){ref-type="app"}) of compound **2b** resembled those of compound **2a**, except for an additional carbonyl carbon at δ~C~ 170.8 and a methyl group at δ~C~ 20.7 (δ~H~ 1.98, s), characteristic of the acetoxyl group ([Table 2](#marinedrugs-14-00134-t002){ref-type="table"}). Moreover, since the signals of the oxymethylene protons (H~2~-10) of compound **2b** appeared as two doublets at δ~H~ 4.13 (*J* = 11.7 Hz) and 4.24 (*J* = 11.7 Hz), ca. 0.7 ppm higher than that of H~2~-10 in compound **2a**, it was clear that the acetoxyl group was on C-10. This was also corroborated by the HMBC correlations ([Table 2](#marinedrugs-14-00134-t002){ref-type="table"}, [Figure 6](#marinedrugs-14-00134-f006){ref-type="fig"}a, [Supplementary Information, Figure S17](#app1-marinedrugs-14-00134){ref-type="app"}) of H~2~-10 and the methyl singlet at δ~H~ 1.98 to the carbonyl of the acetoxyl group (δ~C~ 170.8). Since Compound **2b** could not be obtained as a suitable crystal for X-ray analysis, the absolute configuration of its C-3 could not be determined with certainty. However, as compound **2b** is the acetate derivative of compound **2a**, it was speculated that the stereochemistry of its C-2 should be the same as that of C-2 of compound **2a**, i.e., 2*S*. In order to confirm this hypothesis, the NOESY experiments were carried out. The NOESY spectrum of compound **2b** showed a weak correlation of H-8 to H~3~-9 and not to H~2~-10 ([Figure 6](#marinedrugs-14-00134-f006){ref-type="fig"}b, [Supplementary Information, Figure S18](#app1-marinedrugs-14-00134){ref-type="app"}), similar to what has been observed for compound **2a**. Acid hydrolysis of **2b** gave the product whose structure was confirmed as **2a** by ^1^H and ^13^C NMR data, as well as the optical rotation. Therefore, the absolute configuration of C-2 of **2b** is assigned as 2*S*. Compound **2b** is also a new compound, thus we named it quadricinctapyran B.

The molecular formula C~12~H~12~O~4~ of compound **3**, a white solid (mp 189--191 °C), was established based on the (+)-HRESIMS *m/z* 221.0819 \[M + H\]^+^ (calculated 221.0814), and thus, it is an isomer of compound **2a**. Furthermore, the general features of its ^1^H and ^13^C NMR spectra resembled those of compound **2a**. However, the chemical shift values of some of the proton and carbon signals were slightly different from those observed in compound **2a**. The ^13^C NMR, DEPT and HSQC spectra ([Table 3](#marinedrugs-14-00134-t003){ref-type="table"}, [Supplementary Information, Figures S20 and S22](#app1-marinedrugs-14-00134){ref-type="app"}) exhibited the signals of one conjugated carboxyl carbonyl (δ~C~ 166.7), three quaternary sp^2^ (δ~C~ 161.2, 125.3, 125.0), five methine sp^2^ (δ~C~ 139.5, 134.6, 129.8, 123.5, 119.8), one oxy-quaternary sp^3^ (δ~C~ 70.7), one oxymethylene sp^3^ (δ~C~ 77.0) and one methyl (δ~C~ 26.1) groups. The ^1^H NMR spectrum ([Table 3](#marinedrugs-14-00134-t003){ref-type="table"}, [Supplementary Information, Figure S19](#app1-marinedrugs-14-00134){ref-type="app"}) revealed the existence of three aromatic protons of the 1,2,4-trisubstituted benzene ring, similar to that of compound **2a**, at δ~H~ 7.05, d (*J* = 8.4 Hz), 7.74, dd (*J* = 8.4, 2.1 Hz), 7.89, d (*J* = 2.1 Hz), two olefinic protons of the *cis*-double bond at δ~H~ 5.95, dd (*J* = 12.0, 1.2 Hz) and 6.31, d (*J* = 12.0 Hz), two oxymethylene protons at δ~H~ 3.84, d (*J* = 11.1 Hz) and 4.02, dd (*J* = 11.1, 1.6 Hz), and a methyl singlet at δ~H~ 1.26. That the carboxylic acid functionality was on C-7, and the substituent with a *cis*-double bond was on C-5a was substantiated by the HMBC correlations of H-6 (7.89, d, *J* = 2.1 Hz) to C-10 (δ~C~ 166.7), C-9a (δ~C~ 161.2), C-8 (δ~C~ 129.8) and C-5 (δ~C~ 123.5), of H-5 (δ~H~ 6.31, d, *J* = 12.0 Hz) to C-6 (δ~C~ 134.5) and C-9a and of H-4 (δ~H~ 5.95, dd, d, *J* = 12.0, 1.2 Hz) to C-5a (δ~C~ 125.0) ([Table 3](#marinedrugs-14-00134-t003){ref-type="table"} and [Figure 7](#marinedrugs-14-00134-f007){ref-type="fig"}a, [Supplementary Information, Figure S23](#app1-marinedrugs-14-00134){ref-type="app"}). However, contrary to compound **2a**, compound **3** showed the HMBC correlations of H~2~-2 (δ~H~ 3.84, d, *J* = 11.1 Hz and 4.02, dd, *J* = 11.1, 1.6 Hz) to not only C-4 (δ~C~ 139.5), but also to C-9a ([Table 3](#marinedrugs-14-00134-t003){ref-type="table"} and [Figure 7](#marinedrugs-14-00134-f007){ref-type="fig"}a). Consequently, the benzoic acid moiety was fused with the 2,3,6,7-tetrahydro-oxepine ring through C-5a and C-9a. That the methyl group and the hydroxyl group were on C-3 of the oxepin ring was confirmed by the HMBC correlations of the methyl singlet at δ~H~ 1.26 (H-11) to C-3 (δ~C~ 70.7), C-2 (δ~C~ 77.0) and C-4, as well as of H~2~-2 to C-11 (δ~C~ 26.1) and C-3 ([Table 3](#marinedrugs-14-00134-t003){ref-type="table"} and [Figure 7](#marinedrugs-14-00134-f007){ref-type="fig"}). This was also corroborated by the NOESY correlations of H~3~-11 to OH-3 (δ~H~ 3.39, br), H~2~-2 and H-4 ([Table 3](#marinedrugs-14-00134-t003){ref-type="table"} and [Figure 7](#marinedrugs-14-00134-f007){ref-type="fig"}b, [Supplementary Information, Figure S24](#app1-marinedrugs-14-00134){ref-type="app"}). Therefore, Compound **3** was identified as 3-hydroxy-3-methyl-2,3-dihydro-1-benzoxepine-7-carboxylic acid.

As compound **3** could not be obtained as a suitable crystal for X-ray analysis, an effort to tentatively determine the relative configuration of the stereogenic carbon (C-3) by molecular mechanics conformation analysis and the NOESY experiments was carried out. Stochastic conformational search on the computational models of the structure of **3** with C-3 in *R* configuration, followed by energy minimization, converged to two half-chair conformations for the seven-membered ring C1 and C2, as depicted in [Figure 8](#marinedrugs-14-00134-f008){ref-type="fig"}, regardless of the modelling level of the theory used (MP2/6-311G, PM3, MMFF and MM2). All methods, except for PM3, also agree that conformation C2, with the methyl group in the equatorial position, is more stable by ca. 2 kcal/mol. However, this difference can be attributed to a weak intramolecular hydrogen bond in conformation C2, between HO-3 and O-1, which is not possible in conformation C1. The semi-empirical PM3 method gives less weight to non-ideal intramolecular hydrogen bonds, as compared to the other methods, and assigns virtually the same energy to both conformations of **3**, while still orienting HO-3 towards the seven-membered ring. Since DMSO solvent molecules compete for HO-3 hydrogen bonding, it is more likely that the intramolecular bond is not an important feature of ring conformation C2 and that, in reality, both conformations have approximately the same energy.

Both model conformations of **3** predict hydrogen-hydrogen distances that are similar to within 0.2 Å, with the exception of some distances to the methyl group (H~3~-11). The most notable are to the diastereotopic hydrogens (H~2~-2), partially presented in [Figure 8](#marinedrugs-14-00134-f008){ref-type="fig"}. While both conformations show almost the same distance between H-2a and H-11, a difference is predicted between H-2b and H-11 if the conformation C1 predominates, which should be apparent in the build-up rate of NOESY cross-peaks for small mixing times. Alternatively, the predominance of the conformation C2 would be indicated by two equal strength cross-peaks for H-2a and H-2b in cross-relaxation with H-11. It is observed that the H-2b (δ~H~ 3.84, d, *J* = 11.1 Hz)/H-11 NOESY cross-peak is weak while the H-2a (δ~H~ 4.02, dd, *J* = 11.1, 1.6 Hz)/H-11 is medium, suggesting that the conformation C1 predominates. NOE effective distances, r~eff~, are calculated by \[[@B13-marinedrugs-14-00134]\] : $$r_{eff} = \left( {\frac{1}{3}{\sum\limits_{i}r_{H - 2/H - 10_{i}}^{- 6}}} \right)^{- 1/6}$$

The average effective positions of the three methyl H-11~i~ protons are relative to H-2a or H-2b. The predicted ratio *r*~eff~ (H-2a/H-11)/*r*~eff~ (H-2b/H-11) is 1.40 (1.36, if *r*^−3^ averages are used instead of *r*^−6^). Assuming that the cross-relaxation rate is similar in both cases, the NOE intensities should also have a similar ratio \[[@B14-marinedrugs-14-00134]\]. Since the observed intensities ratio is actually closer to two, the evidence points towards the predominance of the conformation C1. Since, as stated previously, both conformations have similar conformational energy, the higher stability of 3*R*-C1 of **3** (or of its stereoisomer 3*S*-C2) must originate from the ready interaction of the equatorial HO-3 with the hydrogen-bonding solvent and also from a higher entropic rotational freedom of the hydroxyl and methyl groups. The NOESY spectrum also revealed the correlations of both H~2~-2 to H-9. However, only one of the H~2~-2, i.e., the doublet at δ~H~ 3.84 (*J* = 11.1 Hz), showed a weak cross-peak to H-4, while the double doublet at δ~H~ 4.02 (*J* = 11.1, 1.6 Hz) did not give any cross-peak to H-4. This observation led to the conclusion that the plucked oxepin ring should adopt the conformation in which H-2 at δ~H~ 3.84 is near H-4, i.e., in the α (axial), while H-2 at δ~H~ 4.02 is in β (equatorial) positions, which is in agreement with our conformational analysis. A literature search revealed that compound **3** is also a new compound, so we named it quadricinctoxepine.

Compound **4b** was isolated as white crystals (mp, 227--228 °C), and its molecular formula C~12~H~14~O~4~S was established on the basis of the (+)-HRESIMS *m/z* 255.0694 \[M + H\]^+^ (calculated 255.0691). The IR spectrum showed absorption bands for hydroxyl (3442 cm^−1^), conjugated ketone carbonyl (1690 cm^−1^) and aromatic (1622 cm^−1^) groups. The ^13^C NMR, DEPT and HSQC spectra ([Table 4](#marinedrugs-14-00134-t004){ref-type="table"}, [Supplementary Information, Figures S26 and S28](#app1-marinedrugs-14-00134){ref-type="app"}) exhibited the signals of one conjugated ketone carbonyl (δ~C~ 191.2), four quaternary sp^2^ (δ~C~ 151.6, 147.4, 135.7, 120.8), two methine sp^2^ (δ~C~ 118.0, 112.4), one oxy-quaternary sp^3^ (δ~C~ 80.9), one methylene sp^2^ (δ~C~ 48.0) and three methyl (δ~C~ 40.8, 26.1 and 25.7) groups. The ^1^H NMR spectrum ([Table 4](#marinedrugs-14-00134-t004){ref-type="table"}, [Supplementary Information, Figure S25](#app1-marinedrugs-14-00134){ref-type="app"}) exhibited, besides a broad singlet of the phenolic hydroxyl group at δ~H~ 9.85, the signals of two *meta*-coupled aromatic protons at δ~H~ 7.17, d (*J* = 3.1 Hz) and δ~H~ 7.35, d (*J* = 3.1 Hz), two geminally-coupled methylene protons at δ~H~ 2.80, d (*J* = 16.6 Hz) and 2.82, d (*J* = 16.6 Hz) and three methyl singlets at δ~H~ 1.38, s, 1.39, s, and 2.77, s. The chemical shift value of the methyl singlet at δ~H~ 2.77, s (δ~C~ 40.8), indicated that it was on the electron-withdrawing moiety. That compound **4b** was a 2,2,6,8-tetrasubstituted 2,3-dihydro-4*H*-chromen-4-one derivative was supported by the HMBC correlations of H-5 (δ~H~ 7.17, d, *J* = 3.1 Hz) to C-4 (δ~C~ 191.2), C-7 (δ~C~ 118.0) and C-8a (δ~C~ 147.4), of H-7 (δ~H~ 7.35, d, *J* = 3.1 Hz) to C-5 (δ~C~ 112.4), C-8 (δ~C~135.7), C-8a, as well as of H-2 (δ~H~ 2.80, d, *J* = 16.6 Hz and 2.82, d, *J* = 16.6 Hz) to C-3 (δ~C~ 80.9) and C-4 ([Table 4](#marinedrugs-14-00134-t004){ref-type="table"}, [Figure 9](#marinedrugs-14-00134-f009){ref-type="fig"}, [Supplementary Information, Figure S28](#app1-marinedrugs-14-00134){ref-type="app"}). As the HMBC spectrum also exhibited cross-peaks of a broad singlet of the phenolic hydroxyl proton at δ~H~ 9.85 to C-5, C-6 (δ~C~ 151.6) and C-7 and of the singlets of the methyl groups at δ~H~ 1.38 and 1.39 to C-2 (δ~C~ 48.0) and C-3, the hydroxyl group was placed on C-6, and the two methyl groups were placed on C-2. Since this partial structure accounted for only C~11~H~11~O~3~, another portion of the molecule must contain CH~3~SO. That the methyl sulfoxide group was on C-8 was supported by the presence of the deshielded methyl group at δ~H~ 2.77, s (δ~C~ 40.8), as well as by the HBMC cross-peak of H~3~-11 (δ~H~ 2.77, s) to C-8. Final proof of the structure of compound **4b** was provided by its X-ray analysis, and its ORTEP view is shown in [Figure 10](#marinedrugs-14-00134-f010){ref-type="fig"}. Moreover, the ORTEP view also revealed that the absolute configuration of the sulfoxide group in compound **4b** is *R*. A literature search showed that compound **4b** is a new compound, and thus, we have named it quadricinctone B.

The molecular formula C~12~H~14~O~6~ of compound **5** was determined based on the (+)-HRESIMS *m/z* 255.0875 (calculated 255.0869), indicating six degrees of unsaturation. The IR spectrum exhibited absorption bands for hydroxyl (3439 cm^−1^), conjugated ester carbonyl (1660 cm^−1^) and aromatic (1643 cm^−1^) groups. The ^13^C NMR, DEPT and HSQC spectra ([Table 5](#marinedrugs-14-00134-t005){ref-type="table"}, [Supplementary Information, Figures S31 and S33](#app1-marinedrugs-14-00134){ref-type="app"}) exhibited the signals of one conjugated ester carbonyl (δ~C~ 168.8), five quaternary sp^2^ (δ~C~ 162.9, 161.3, 144.6, 113.5, 98.9), one methine sp^2^ (δ~C~ 99.9), one quaternary sp^3^ of a hemiketal (δ~C~ 104.8), one methine sp^3^ (δ~C~ 34.9), one oxymethylene sp^3^ (δ~C~ 63.7) and two methyl (δ~C~ 16.3 and 9.8) carbons. The ^1^H NMR spectrum ([Table 5](#marinedrugs-14-00134-t005){ref-type="table"}, [Supplementary Information, Figure S30](#app1-marinedrugs-14-00134){ref-type="app"}) exhibited, besides a singlet of one aromatic proton at δ~H~ 6.27, a singlet of a hydrogen-bonded phenolic hydroxyl at δ~H~ 11.24 and a broad signal of another phenolic hydroxyl at δ~H~ 10.62, two broad signals of the hydroxyl groups at δ~H~ 5.26 and 7.07, one broad doublet of two methylene protons at δ~H~ 3.65 (*J* = 16.6 Hz), a broad signal of one methine proton at δ~H~ 3.26, one methyl doublet at δ~H~ 1.06 (*J* = 7.2 Hz) and one methyl singlet at δ~H~ 1.98. That compound **5** was a 3,3,4,5,6,8-hexasubstituted 3,4-dihydro-1*H*-isochromen-1-one was supported by the HBMC correlations of OH-8 (δ~H~ 11.24, s) to C-8 (δ~C~ 161.3), C-7 (δ~C~ 99.9), C-8a (δ~C~ 98.9) and of H-7 (δ~H~ 6.27, s) to C-5 (δ~C~ 113.5), C-6 (δ~C~ 162.9), C-8 and C-8a ([Table 5](#marinedrugs-14-00134-t005){ref-type="table"}, [Figure 11](#marinedrugs-14-00134-f011){ref-type="fig"}, [Supplementary Information, Figure S34](#app1-marinedrugs-14-00134){ref-type="app"}). Since the methyl singlet at δ~H~ 1.98 gave HMBC cross-peaks to C-5 and the carbons at δ~C~ 144.6 and 162.9 ([Table 5](#marinedrugs-14-00134-t005){ref-type="table"}, [Figure 11](#marinedrugs-14-00134-f011){ref-type="fig"}), the methyl group (δ~H~ 1.98; δ~C~ 9.8) and another hydroxyl group (δ~H~ 10.62, br) were placed on C-5 and C-6, respectively, and the carbon signals at δ~C~ 144.6 and 162.9 were assigned for C-4a and C-6, respectively. On the other hand, the COSY spectrum ([Table 5](#marinedrugs-14-00134-t005){ref-type="table"}, [Supplementary Information, Figure S32](#app1-marinedrugs-14-00134){ref-type="app"}) showed cross-peaks of the broad signal at δ~H~ 3.26 to the methyl doublet at δ~H~ 1.06 (*J* = 7.2 Hz) and of the broad signal at δ~H~ 5.26 to the broad doublet at δ~H~ 3.65 (*J* = 16.6 Hz), while the HMBC spectrum ([Table 5](#marinedrugs-14-00134-t005){ref-type="table"}, [Figure 11](#marinedrugs-14-00134-f011){ref-type="fig"}) gave cross-peaks of the methyl doublet at δ~H~ 1.06 (*J* = 7.2 Hz) to C-4a, C-4 (δ~C~ 34.9), and the signal of the quaternary carbon at δ~C~ 104.8 (C-3), the methyl and the hydroxymethyl substituents were placed on C-4 and C-3, respectively. Therefore, another hydroxyl group (δ~H~ 7.07, br) was on C-3. This was supported by the chemical shift value of C-3, which is typical for a hemiketal carbon. Since compound **5** could be obtained as a suitable crystal (mp. 223--224 °C), its X-ray analysis was performed. The ORTEP view of compound **5**, shown in [Figure 12](#marinedrugs-14-00134-f012){ref-type="fig"}, not only confirmed the proposed structure, but also determined the absolute configuration of C-3 and C-4 as 3*S*, 4*R*. Since compound **5** is a new compound, it was named quadricinctone C.

Compound **6a** was also isolated as white crystals (mp. 149--150 °C), and its molecular formula C~12~H~14~O~4~ was determined based on the (+)-HRESIMS *m/z* 223.9067 \[M + H\]^+^ (calculated 223.9070), indicating six degrees of unsaturation. The IR spectrum showed absorption bands for hydroxyl (3417 cm^−1^), a conjugated carbonyl (1681 cm^−1^) and aromatic (1634 cm^−1^) groups. The ^13^C NMR, DEPT and HSQC spectra ([Table 6](#marinedrugs-14-00134-t006){ref-type="table"}, [Supplementary Information, Figures S36 and S38](#app1-marinedrugs-14-00134){ref-type="app"}) exhibited the signals of one conjugated carboxyl carbonyl (δ~C~ 167.2), two quaternary sp^2^ (δ~C~ 128.2, 122.6), one oxy-quaternary sp^2^ (δ~C~ 163.7), three methine sp^2^ (δ~C~ 130.4, 126.4, 108.4), one oxy-quaternary sp^3^ (δ~C~ 70.0), one oxymethine sp^3^ (δ~C~ 90.2), one methylene sp^2^ (δ~C~ 29.3) and two methyl (δ~C~ 25.9 and 24.9) carbons. The ^1^H NMR spectrum ([Table 6](#marinedrugs-14-00134-t006){ref-type="table"}, [Supplementary Information, Figure S35](#app1-marinedrugs-14-00134){ref-type="app"}) showed signals of three aromatic protons of the 1,2,4-trisubstituted benzene ring at δ~H~ 7.75, d (*J* = 1.8 Hz), 7.72, dd (*J* = 8.3, 1.8 Hz), 6.80, d (*J* = 8.3 Hz), in addition to a broad signal of the hydroxyl proton at δ~H~ 12.49, a triplet of one proton at δ~H~ 4.64 (*J* = 8.9 Hz), a doublet of two protons at δ~H~ 3.17 (*J* = 8.9 Hz) and two methyl singlets at δ~H~ 1.13 and 1.14. That the 1,2,4-trisubstituted benzene ring was part of 2,5-disubstituted 2,3-dihydro-1-benzofuran was supported by the COSY correlations of H-6 (δ~H~ 7.72, dd, *J* = 8.3, 1.8 Hz) to H-4 (δ~H~ 7.75, d, *J* = 1.8 Hz) and H-7 (δ~H~ 6.80, d, *J* = 8.3 Hz) and of H-2 (δ~H~ 3.17, *J* = 8.9 Hz) to H-3 (δ~H~ 4.64, *J* = 8.9 Hz)([Table 6](#marinedrugs-14-00134-t006){ref-type="table"}, [Figure 13](#marinedrugs-14-00134-f013){ref-type="fig"}a, [Supplementary Information, Figure S37](#app1-marinedrugs-14-00134){ref-type="app"}), as well as of the HMBC correlations of H-4 to C-6 (δ~C~ 130.4) and C-7a (δ~C~ 163.7), of H-6 to C-4 (δ~C~ 126.4), of H-3 to C-2 (δ~C~ 90.2), C-3a (δ~C~ 128.2) and C-7a and of H-7 to C-3a, C-7a and C-5 (δ~C~ 122.6) ([Table 6](#marinedrugs-14-00134-t006){ref-type="table"}, [Figure 13](#marinedrugs-14-00134-f013){ref-type="fig"}a, [Supplementary Information, Figure S39](#app1-marinedrugs-14-00134){ref-type="app"}). That the carboxyl group was on C-5 was supported by the HMBC correlations of H-4 and H-6 to the conjugated carbonyl at δ~C~ 167.2 ([Table 6](#marinedrugs-14-00134-t006){ref-type="table"}, [Figure 13](#marinedrugs-14-00134-f013){ref-type="fig"}a), along with the presence of a broad signal at δ~H~ 12.49, which is characteristic of a hydroxyl group of carboxylic acid. In the same manner, that the 2-hydroxypropyl substituent was placed on C-2 was evidenced by the HMBC correlations of H-2 (δ~H~ 4.64, *J* = 8.9 Hz) to C-3 (δ~C~ 29.3), C-1′ (δ~C~ 70.0), C-2′ (δ~C~ 24.9), C-3′ (δ~C~ 25.9) ([Table 6](#marinedrugs-14-00134-t006){ref-type="table"}, [Figure 13](#marinedrugs-14-00134-f013){ref-type="fig"}a), as well as by the NOESY correlations of H-2 to H-3, H~3~-2′ (δ~H~ 1.14, s) and H~3~-3′ (δ~H~ 1.13, s)([Figure 13](#marinedrugs-14-00134-f013){ref-type="fig"}b). Therefore, compound **6a** was identified as 2-(2-hydroxypropan-2-yl)-2,3-dihydro-1-benzofuran-5-carboxylic acid. A literature search revealed that compound **6a** has the same flat structure as anodendroic acid (2-(1-hydroxy-1-methylethyl)-2,3-dihydrobenzofuran-5-carboxylic acid), which was first isolated from the stem of *Anodendron affine* Durce \[[@B15-marinedrugs-14-00134]\]. Anodendroic acid was later synthesized by Yamaguchi et al. \[[@B16-marinedrugs-14-00134]\]; however, its ^1^H NMR data (DMSO-*d*~6~) were slightly different from those reported by Shima et al. \[[@B15-marinedrugs-14-00134]\]. Anodendroic acid was also obtained by basic hydrolysis of its methyl ester, a constituent of *Eriodictyon sessilifolium* \[[@B17-marinedrugs-14-00134]\], and also by biotransformation of 3-(γ,γ-dimethylallyl)-*p*-coumaric acid \[[@B18-marinedrugs-14-00134]\]. It is interesting to note that, in all of these reports, the identity of anodendroic acid was achieved by comparing its melting point, ^1^H NMR and MS data with those reported by Shima et al. \[[@B15-marinedrugs-14-00134]\], while no stereochemistry of C-2 was indicated. However, when compared to the ^1^H NMR and other physical data of compound **6a** with those reported for anodendroic acid by Shima et al. \[[@B15-marinedrugs-14-00134]\], it was found that the ^1^H NMR data of anodendroic acid (in pyridine-*d*~6~) \[[@B15-marinedrugs-14-00134]\] were slightly different from those of compound **6a** (in DMSO-*d*~6~). Therefore, it was not possible to compare these ^1^H NMR data, since they were obtained in different solvents. Interestingly, the ^1^H NMR data, obtained in DMSO-*d*~6~ by Yamaguchi et al. \[[@B16-marinedrugs-14-00134]\], were also slightly different from those of compound **6a**. The obvious differences between anodendroic acid \[[@B15-marinedrugs-14-00134]\] and compound **6a** are their melting points and optical rotations. While anodendroic acid (mp. 212--214 °C) is laevorotatory (${\lbrack\alpha\rbrack}_{D}^{26}$ −19°, *c* 0.7, EtOH) \[[@B15-marinedrugs-14-00134]\], compound **6a** (mp. 149--150 °C) is dextrorotatory (${\lbrack\alpha\rbrack}_{D}^{20}$ +74°, *c* 0.03, MeOH). Consequently, we concluded that the structure of compound **6a** is different from that of anodendroic acid. This fact has prompted us to investigate the stereochemistry of compound **6a**. Since Compound **6a** was obtained as a suitable crystal for X-ray diffraction, its X-ray analysis was carried out. The ORTEP view of compound **6a** shown in [Figure 14](#marinedrugs-14-00134-f014){ref-type="fig"} not only confirmed its proposed structure, but also revealed the absolute configuration for C-2 as 2*R*. Therefore, compound **6a** is a new compound, and we have named it quadricinctafuran A. Since anodendroic acid exhibited the opposite sign of rotation to that of compound **6a**, it is probable that the absolute configuration of its C-2 is 2*S*. This is not unusual, since fomannoxin, another 2,3-dihydrobenzofuran derivative, also showed the opposite optical rotation and has the opposite absolute configuration to tremetone, even though they have very similar structures \[[@B16-marinedrugs-14-00134]\].

The (+)-HRESIMS of compound **6b** gave the \[M + H\]^+^ at *m/z* 239.0919 (calculated 239.0919), indicating its molecular formula C~12~H~14~O~5~ and, therefore, six degrees of unsaturation. The general features of its ^1^H and ^13^C NMR spectra resembled those of compound **6a**. The ^13^C NMR, DEPT and HSQC spectra ([Table 6](#marinedrugs-14-00134-t006){ref-type="table"}, [Supplementary Information, Figures S42 and S44](#app1-marinedrugs-14-00134){ref-type="app"}) exhibited the signals of one conjugated carboxyl carbonyl (δ~C~ 167.2), two quaternary sp^2^ (δ~C~ 128.4, 122.6), one oxy-quaternary sp^2^ (δ~C~ 163.6), three methine sp^2^ (δ~C~ 130.8, 126.4, 108.4), one oxy-quaternary sp^3^ (δ~C~ 72.5), one oxymethine sp^3^ (δ~C~ 86.5), one methylene sp^2^ (δ~C~ 28.7), one oxymethylene sp^2^ (δ~C~ 66.7) and one methyl (δ~C~ 20.0) carbons. The ^1^H NMR and COSY spectra ([Table 6](#marinedrugs-14-00134-t006){ref-type="table"}, [Supplementary Information, Figures S41 and S43](#app1-marinedrugs-14-00134){ref-type="app"}) showed similar proton signals of the 2,3-dihydro-1-benzofuran-5-carboxylic acid nucleus to those of **6a**. However, it exhibited only one methyl singlet at δ~H~ 1.09 and another singlet of oxymethylene protons at δ~H~ 3.33, instead of two methyl singlets as in compound **6a**. Therefore, the difference between the structures of compounds **6a** and **6b** resides in the substitutions on C-2. That the substituent on C-2 of compound **6b** was 1,2-dihydroxypropyl was evidenced by not only its molecular formula (C~12~H~14~O~5~), which has one more oxygen atom than that of compound **6a** (C~12~H~14~O~4~), but also the presence of the oxymethylene carbon at δ~C~ 66.7 (C-2′; δ~H~ 3.33, s). Moreover, the chemical shift value of C-2 (δ~C~ 86.5) was nearly 4 ppm lower than that of compound **6a** (δ~C~ 90.2). Thus, compound **6b** was identified as 2-(1,2-dihydroxypropan-2-yl)-2,3-dihydro-1-benzofuran-5-carboxylic acid. This was confirmed by the HMBC correlations of H~3~-3′ (δ~H~ 1.09) to C-1′ (δ~C~ 72.5) and C-2′ (δ~C~ 66.7), as well of H~2~-2′ (δ~H~ 3.33, s) to C-1′ (δ~C~ 72.5) and C-3′ (δ~C~ 20.0) ([Figure 15](#marinedrugs-14-00134-f015){ref-type="fig"}, [Supplementary Information, Figure S45](#app1-marinedrugs-14-00134){ref-type="app"}). Since compound **6b** could not be obtained as suitable crystals for X-ray crystallography, it was not possible to determine the absolute configuration of C-2 by X-ray analysis. Moreover, as compound **6b** also has a tertiary hydroxyl group on C-1′ and a primary hydroxyl group on C-2′, it was not possible to determine the absolute configurations of C-2 and C-1′ by Mosher's method. On the other hand, since the methyl group on C-1 in compound **6a** was replaced by the hydroxymethyl group incompound **6b**, it is legitimate to postulate that compounds **6b** is derived from compound **6a**. Consequently, the absolute configuration of C-2 of compound **6b** should be the same as that of compound **6a**, i.e., 2*R*. However, it is not yet possible to determine the absolute configuration of C-1′. Compound **6b** is also a new compound, and we have named it quadricinctafuran B.

Compound **7** was also isolated as white crystals (mp. 196--197 °C), and its molecular formula C~14~H~12~O~5~ was established on the basis of the (+)-HRESIMS *m/z* 237.0792 \[M + H\]^+^ (calculated 237.0763), indicating seven degrees of unsaturation. The IR spectrum showed absorption bands for hydroxyl (3404 cm^−1^), conjugated ketone carbonyl (1708 cm^−1^), conjugated carboxyl carbonyl (1670 cm^−1^) and aromatic (1558, 1540 cm^−1^) groups. The ^13^C NMR, DEPT and HSQC spectra ([Table 7](#marinedrugs-14-00134-t007){ref-type="table"}, [Supplementary Information, Figures S48 and S50](#app1-marinedrugs-14-00134){ref-type="app"}) exhibited the signals of one conjugated ketone carbonyl (δ~C~ 191.1), one conjugated carboxyl carbonyl (δ~C~ 166.4), one oxy-quaternary sp^2^ (δ~C~ 162.9), two quaternary sp^2^ (δ~C~ 123.0, 119.6), three methine sp^2^ (δ~C~ 136.4, 127.5, 118.5), one oxy-quaternary sp^3^ (δ~C~ 83.0), one oxymethylene sp^2^ (δ~C~ 66.8), one methylene sp^2^ (δ~C~ 43.4) and one methyl (δ~C~ 21.2) carbons. The ^1^H NMR spectra ([Table 7](#marinedrugs-14-00134-t007){ref-type="table"}, [Supplementary Information, Figure S47](#app1-marinedrugs-14-00134){ref-type="app"}) exhibited, besides the signals of three aromatic protons of the 1,2,4-trisubstituted benzene ring at δ~H~ 8.26, d (*J* = 2.3 Hz), 8.04, dd (*J* = 8.7, 2.3 Hz), 7.07, d (*J* = 8.7 Hz), a methyl singlet at δ~H~ 1.30, two pairs of geminally-coupled methylene protons at δ~H~ 2.74, d (*J* = 16.7 Hz)/3.00, d (*J* = 16.7 Hz) and δ~H~ 3.49, dd (*J* = 11.6, 4.5 Hz)/3.59, dd (*J* = 11.6, 4.2 Hz); the latter showed COSY correlations with the broad triplet of the hydroxyl proton at δ~H~ 5.26 ([Table 7](#marinedrugs-14-00134-t007){ref-type="table"}, [Figure 16](#marinedrugs-14-00134-f016){ref-type="fig"}a, [Supplementary Information, Figure S49](#app1-marinedrugs-14-00134){ref-type="app"}). As the HMBC spectrum exhibited correlations of the aromatic proton signal at δ~H~ 8.26, d (*J* = 2.3 Hz, H-5) to the oxy-quaternary sp^2^ carbon at δ~C~ 162.9 (C-8a), as well as to the conjugated ketone carbonyl carbon at δ~C~ 191.1 (C-4) and the methine sp^2^ at δ~C~ 136.4 (C-7) ([Table 7](#marinedrugs-14-00134-t007){ref-type="table"}, [Figure 16](#marinedrugs-14-00134-f016){ref-type="fig"}a, [Supplementary Information, Figure S51](#app1-marinedrugs-14-00134){ref-type="app"}), the ketone moiety was placed on C-4a. Additionally, the HMBC spectrum also showed correlations of H-8 (δ~H~ 7.07, d, *J* = 8.7 Hz) to C-8a and the quaternary sp^2^ carbons at δ~C~ 123.0 and 119.6; they were therefore assigned to C-4a and C-6, respectively ([Table 7](#marinedrugs-14-00134-t007){ref-type="table"}, [Figure 16](#marinedrugs-14-00134-f016){ref-type="fig"}a). The presence of the 1-hydroxy-2-methyl-2-oxypropyl moiety was supported by the HMBC correlations of the methyl singlet at δ~H~ 1.30 (CH~3~-9) to the oxy-quaternary sp^3^ carbon at δ~C~ 83.0 (C-2), the oxymethylene sp^3^ carbon at δ~C~ 66.8 (C-10) and the methylene sp^3^ carbon at δ~C~ 43.4 (C-3), as well as of the H~2~-3 (δ~H~ 2.74, d, *J* = 16.7 Hz/3.00, d, *J* = 16.7 Hz) to C-2, C-9 (δ~C~ 21.2) and C-10 ([Table 7](#marinedrugs-14-00134-t007){ref-type="table"}, [Figure 16](#marinedrugs-14-00134-f016){ref-type="fig"}a). Since H~2~-3 also gave a HMBC cross-peak to C-4, the 1-hydroxy-2-methyl-2-oxypropyl moiety was linked to C-4. Due to the fact that these two moieties accounted for only C~11~H~12~O~4~, it was concluded that the carboxyl group (δ~C~ 166.4, δ~H~ 12.69 br) was on C-6. Therefore, compound **7** was identified as 2-(hydroxymethyl)-2-methyl-4-oxo-3,4-dihydro-2*H*-chromene-6-carboxylic acid. As compound **7** was obtained as a suitable crystal for an X-ray diffraction, its X-ray analysis was carried out. The ORTEP view of compound **7**, shown in [Figure 17](#marinedrugs-14-00134-f017){ref-type="fig"}, revealed the absolute configuration for C-2 as 2*S*. A literature search revealed that compound **7** is also a new compound, so we named it quadricinctone D.

In order to establish the conformation of the 2,3-dihydro-*4H*-pyran-4-one, analysis of the NOESY correlations was carried out. The NOESY spectrum ([Table 7](#marinedrugs-14-00134-t007){ref-type="table"}, [Figure 16](#marinedrugs-14-00134-f016){ref-type="fig"}b, [Supplementary Information, Figure S52](#app1-marinedrugs-14-00134){ref-type="app"}) exhibited not only a strong correlation of H-7 to H-8, but also week correlations of H~3~-9 to H-5 and H-8. Therefore, CH~3~-9 is in the α-axial position. Additionally, since H~3~-9 also exhibited a strong cross-peak with the signal of the methylene proton at δ~H~ 2.74, d (*J* = 16.7 Hz), and a weak cross-peak with the proton signal at δ~H~ 3.00, d (*J* = 16.7 Hz), the former was assigned to H-3α and the latter to H-3β. It is interesting to observe that the structure of compound **7** is analogous to the structure of compound **3** in that it also exhibits the same methyl-methylene bridge structural feature (at C-9 and C-3), with the same relative intensity of NOESY cross-peaks between the protons of the two groups and with similar conformational energies for the two half-chair conformations of the non-aromatic ring. Therefore, the conclusions drawn for compound **3** are also valid for compound **7**, whose stereochemistry is unequivocally defined by X-ray analysis.

Compounds **1** and **5** can be hypothesized as originating from the pentaketide intermediate (I). Methylation (by SAM) gives II, which undergoes cyclization and enolization to give the intermediate III. Methylation of the phenolic hydroxyl groups and the α-carbon of the carbonyl ketone leads to the intermediate IV. Enolization, followed by a lactonization, originates V, which undergoes hydration to give VI, and oxidation of one of the methyl groups gives rise to compound **5**. Alternatively, oxidation of the α-carbon of the side chain of IV leads to the intermediate VII, which, after lactonization and reduction of the ketone carbonyl, gives rise to compound **1** ([Figure 18](#marinedrugs-14-00134-f018){ref-type="fig"}).

Biosynthetically, compounds **2a**, **2b**, **4a**, **4b**, **6a**, **6b** and **7** are of mixed origin, i.e., shikimic acid and mevalonic acid pathways, similar to that proposed for fomannoxin \[[@B19-marinedrugs-14-00134]\], as depicted in [Figure 19](#marinedrugs-14-00134-f019){ref-type="fig"}. Elimination of pyruvate from chorismate (IX) by chorismate pyruvate lyase leads to the formation of *p*-hydroxybenzoic acid (X), which after prenylation by DMAPP (XI), originates the intermediate XII. Epoxidation and cyclization of XII, via Route *a*, leads to a formation of the furan ring in compound **6a** and after oxidation of one of the methyl groups leads to compound **6b**. On the other hand, cyclization via Route *b* leads to the formation of the pyran ring in XIV. Dehydration and oxidation of one of the methyl groups originates compound **2a**, which after acetylation of the primary alcohol function of the side chain will originate compound **2b**. Alternatively, the intermediate XIV can also undergo dehydration, reduction and oxidation to give the ketone function in compound **7**. Oxidative decarboxylation of compound **7** leads to the formation of compound **4a**, which after sulfinylation of the benzene ring originates compound **4b**. However, it is possible that the introduction of the methyl sulfoxide group to the aromatic ring could happen before cyclization.

Compound **3** is also derived from a prenylation of *p*-hydroxybenzoic acid (X); however, it can occur with IPP (XVI) instead of DMAPP (XI). Epoxidation of the double bond of the side chain of XVII, followed by cyclization of XVIII leads to the formation of an oxepin ring in XIX. Oxidation and dehydration of the oxepin ring will lead to the formation of compound **3**, as depicted in [Figure 20](#marinedrugs-14-00134-f020){ref-type="fig"}.

Compounds **1**--**7** were evaluated for their antibacterial activity against Gram-positive and Gram-negative bacteria, as well as multidrug-resistant isolates from the environment, according to the previously described protocol \[[@B6-marinedrugs-14-00134]\], as well as for their antifungal activity against yeast (*Candida albicans* ATCC 10231), filamentous fungus (*Aspergillus fumigatus* ATCC 46645) and dermatophyte (*Trichophyton rubrum* FF5) in the antifungal assay \[[@B20-marinedrugs-14-00134]\]. The results showed that none of the tested compounds exhibited significant antibacterial activity (MIC \> 256 μg/mL) or antifungal activity (MIC \> 512 μg/mL). These compounds were also evaluated for their in vitro growth inhibitory activity against the MCF-7 (breast adenocarcinoma), NCI-H460 (non-small cell lung cancer) and A375-C5 (melanoma) cell lines by the protein binding dye SRB method \[[@B21-marinedrugs-14-00134]\], and they did not show any activity in this assay (GI~50~ \> 150 mM).

3. Experimental Section {#sec3-marinedrugs-14-00134}
=======================

3.1. General Procedure {#sec3dot1-marinedrugs-14-00134}
----------------------

Melting points were determined on a Bock monoscope and are uncorrected. Optical rotations were measured on an ADP410 Polarimeter (Bellingham + Stanley Ltd., Tunbridge Wells, Kent, U.K.). Infrared spectra were recorded in a KBr microplate in a FTIR spectrometer Nicolet iS10 from Thermo Scientific (Waltham, MA, USA) with the Smart OMNI-Transmission accessory (Software 188 OMNIC 8.3). UV spectra were taken in CHCl~3~ and were recorded on a Varian CARY 100 spectrophotometer. ^1^H and ^13^C NMR spectra were recorded at ambient temperature on a Bruker AMC instrument (Bruker Biosciences Corporation, Billerica, MA, USA) operating at 300.13 and 75.4 MHz, respectively. High resolution mass spectra were measured with a Waters Xevo QToF mass spectrometer (Waters Corporations, Milford, MA, USA) coupled to a Waters Acquity UPLC system. A Merck (Darmstadt, Germany) silica gel GF~254~ was used for preparative TLC, and a Merck Si gel 60 (0.2--0.5 mm) was used for column chromatography.

3.2. Extraction and Isolation {#sec3dot2-marinedrugs-14-00134}
-----------------------------

The strain KUFA 0081 was isolated from the marine sponge *Clathria reinwardti*, which was collected, by scuba diving at a depth of 15--20 m, from the coral reef at Samae San Island (12°34′ 36.64″ N 100°56′ 59.69″ E) in the Gulf of Thailand, Chonburi Province, in July 2013. The sponge was washed with 0.06% sodium hypochlorite solution for 1 min, followed by sterilized seawater 3 times and then dried on sterile filter paper, cut into small pieces (5 × 5 mm) and placed on a malt extract agar (MEA) medium containing 70% seawater and 300 mg/L of streptomycin sulphate, then incubated at 28 °C for 7 days, after which the hyphal tips were transferred onto a slant MEA and maintained as pure culture for further identification. The fungus was identified as *Neosartorya quadricincta* (E. Yuill) Malloch & Cain by one of us (T.D.), based on morphological characteristics, such as colony growth rate and growth pattern on standard media, namely Czapek's agar, Czapek yeast autolysate agar and malt extract agar. Microscopic characteristics, including size, shape and the ornamentation of ascospores, were examined under light and scanning electron microscopes. This identification was supported by sequence analysis of the β-tubulin, calmodulin and actin genes as described in the previous report \[[@B22-marinedrugs-14-00134]\]. *Neosartorya quadricincta* was also confirmed by the analysis sequence of the internal transcribed spacer (ITS) gene according the procedure previously described by us \[[@B7-marinedrugs-14-00134]\]. Its gene sequences were deposited in GenBank with Accession Numbers KM095492 and KT201525, respectively. The pure cultures were deposited as KUFA0081 at Kasetsart University Fungal Collection, Department of Plant Pathology, Faculty of Agriculture, Kasetsart University, Bangkok, Thailand.

The fungus was cultured for one week at 28 °C in 10 Petri dishes (i.d. 90 mm) containing 25 mL of MEA. In order to obtain the mycelial suspension, the mycelial plugs were transferred to two 500-mL Erlenmeyer flasks containing 200 mL of potato dextrose broth and then incubated on a rotary shaker at 120 rpm at 28 °C for 4 days. Fifty 1000-mL Erlenmeyer flasks, each containing 300 g of cooked rice, were autoclaved at 121 °C for 15 min, then inoculated with 20 mL of mycelial suspension of *N. quadricincta* and incubated at 28 °C for 30 days, after which the mouldy rice was macerated in ethyl acetate (25 L total) for 7 days and then filtered. The ethyl acetate solution was concentrated under reduced pressure to yield 176.5 g of crude ethyl acetate extract, which was dissolved in 500 mL of CHCl~3~ and then washed with H~2~O (3 × 500 mL). The organic layers were combined and dried with anhydrous Na~2~SO~4~, filtered and evaporated under reduced pressure to give 31.1 g of the crude chloroform extract, which was applied on a column of silica gel (440 g) and eluted with mixtures of petrol-CHCl~3~ and CHCl~3~-Me~2~CO; 250-mL fractions were collected as follows: Frs 1--15 (petrol-CHCl~3~, 1:1), 16--55 (petrol-CHCl~3~, 3:7), 56--118 (petrol-CHCl~3~, 1:9), 119--284 (CHCl~3~-Me~2~CO, 9:1), 285--329 (CHCl~3~-Me~2~CO, 7:1), 330--359 (CHCl~3~-Me~2~CO, 1:1). Frs 175--181 were combined (250 mg) and purified by TLC (silica gel G254, CHCl~3~-Me~2~CO-HCO~2~H, 3:2:0.01) to give 86.8 mg of **1** and 15.0 mg of **2b**. Frs 182--197 were combined (565.1 mg) and purified by TLC (silica gel G254, CHCl~3~-Me~2~CO-HCO~2~H, 17:3:0.02) to give 35.1 mg of **1** and 14.3 mg of **2b**. Frs 224--235 were combined (249.3 mg) and purified by TLC (silica gel G254, CHCl~3~-Me~2~CO-HCO~2~H, 4:1:0.01) to give 11.4 mg of **4a** \[[@B12-marinedrugs-14-00134]\]. Frs 236--285 were combined (1.2 g), applied over a column chromatography of silica gel (42 g) and eluted with mixtures of petrol-CHCl~3~ and CHCl~3~-Me~2~CO, wherein 100-mL subfractions were collected as follows: sfrs 1--17 (petrol-CHCl~3~, 1:9), 18--61 (CHCl~3~-Me~2~CO,9:1). Sfrs 24--33 were combined (423.4 mg) and precipitated in a mixture of CHCl~3~ and Me~2~CO to give a white solid (46.2 mg), which was further recrystallized in a mixture of CHCl~3~ and Me~2~CO to give 9.4 mg of white crystals of **6a**, and the mother liquor was purified by TLC (silica gel G254, CHCl~3~-Me~2~CO-HCO~2~H, 9:1:0.01) to give 23.2 mg of **6a** and 4.9 mg of **2a**. The mother liquor of sfrs 24--33 (133.0 mg) was purified by TLC (silica gel G254, CHCl~3~-Me~2~CO-HCO~2~H, 7: 3:0.01) to give 41.1 mg of **2a** and 12.4 mg of **3**. Sfrs 34--39 were combined (77.7 mg) and purified with TLC (silica gel G254, CHCl~3~-Me~2~CO-HCO~2~H, 3: 1:0.01) to give 7.9 mg of **4b** and 17.1 mg of **2a**. Sfrs 40--61 were combined (496.4 mg) and purified by TLC (silica gel G254, CHCl~3~-Me~2~CO-HCO~2~H, 4: 1:0.01) to give 22.7 mg of **5**. Frs 307--315 were combined (291.0 mg), applied over a column chromatography of Sephadex LH-20 (10 g) and eluted with a 1:1 mixture of CHCl~3~: MeOH to give twelve 1-mL sub-fractions. Sfrs 9--12 were combined and purified by TLC (silica gel G254, CHCl~3~-Me~2~CO-HCO~2~H, 3: 2:0.01) to give 13.4 mg of **6b** and 9.4 mg of **7**. Frs 316--359 were combined (1.2 g), applied over a column chromatography of Sephadex LH-20 (10 g) and eluted with a 1:1 mixture of CHCl~3~: MeOH to give twenty-one 1-mL sub-fractions. Sfrs 12--21 were combined (645.7 mg), applied over a column chromatography of Sephadex LH-20 (10 g) and eluted with a 1:1 mixture of CHCl~3~: MeOH to give sixteen 1-mL fractions. Ssfrs 5--16 were combined (597.5), applied over a column chromatography of silica gel (15 g) and eluted with a mixture of petrol-CHCl~3~ and CHCl~3~-Me~2~CO, wherein 100-mL fractions were collected as follows: frs 1--8 (petrol-CHCl~3~, 1:9), 9--28 (CHCl~3~-Me~2~CO, 9:1), 29--41 ((CHCl~3~-Me~2~CO, 7:3). Frs 17--18 were combined (47.4 mg) and purified by TLC (silica gel G254, CHCl~3~-Me~2~CO-HCO~2~H, 3: 2:0.01) to give 20.8 mg of **6b**.

### 3.2.1. Quadricinctone A: 3-(1-Hydroxyethyl)-5,7-dimethoxy-3,4-dimethyl-2-benzofuran-1(3*H*)-one (**1**) {#sec3dot2dot1-marinedrugs-14-00134}

White crystals; mp 176--177 °C (petrol/CHCl~3~); ${\lbrack\alpha\rbrack}_{D}^{20}$ −59° (*c* 0.05, CHCl~3~); UV (MeOH) λ~max~ (log ε) 233 (4.39), 260 (4.03), 298 (3.78) nm; IR (KBr) υ~max~ 3455, 2981, 2490, 1723, 1612, 1596, 1499, 1467, 1432, 1228 cm^−1^; ^1^H and ^13^C NMR, see [Table 1](#marinedrugs-14-00134-t001){ref-type="table"}; HRESIMS *m/z* 267.1243 \[M + H\]^+^ (calculated for C~14~H~19~O~5~, 267.1332).

### 3.2.2. Quadricinctapyran A: 2-(Hydroxymethyl)-2-methyl-2*H*-chromene-6-carboxylic acid (**2a**) {#sec3dot2dot2-marinedrugs-14-00134}

White crystals; mp 147--148 °C (CHCl~3~/Me~2~CO); ${\lbrack\alpha\rbrack}_{D}^{20}$ +30° (*c* 0.03, MeOH); UV (MeOH) λ~max~ (log ε) 237 (4.61) nm; IR (KBr) υ~max~ 3447, 2922, 2359, 2341, 1696, 1647, 1609, 1578, 1490, 143, 1301, 1267 cm^−1^; ^1^H and ^13^C NMR, see [Table 2](#marinedrugs-14-00134-t002){ref-type="table"}; HRESIMS *m/z* 221.0820 \[M + H\]^+^ (calculated for C~12~H~13~O~4~, 221.0814).

### 3.2.3. Quadricinctapyran B: 2-\[(Acetyloxy)methyl\]-2-methyl-2*H*-chromene-6-carboxylic acid (**2b**). {#sec3dot2dot3-marinedrugs-14-00134}

White solid; mp 118--119 °C (petrol/CHCl~3~); ${\lbrack\alpha\rbrack}_{D}^{20}$ +58° (*c* 0.07, CHCl~3~); UV (MeOH) λ~max~ (log ε) 201 (4.13), 237 (4.47) nm; IR (KBr) υ~max~ 3441, 2986, 2943, 1745, 1678, 1640, 1607, 1574, 1453, 1419, 1297, 1264, 1228 cm^−1^; ^1^H and ^13^C NMR, see [Table 2](#marinedrugs-14-00134-t002){ref-type="table"}; HRESIMS *m/z* 263.0971 \[M + H\]^+^ (calculated for C~14~H~15~O~5~, 263.0919).

### 3.2.4. Quadricinctoxepine: 3-Hydroxy-3-methyl-2,3-dihydro-1-benzoxepine-7-carboxylic acid (**3**) {#sec3dot2dot4-marinedrugs-14-00134}

White solid; mp 189--191 °C (CHCl~3~/Me~2~CO); ${\lbrack\alpha\rbrack}_{D}^{20}$ +21° (*c* 0.07, MeOH); UV (MeOH) λ~max~ (log ε) 234 (4.50) nm; IR (KBr) υ~max~ 3404, 2921, 2359, 2342, 1701, 1606, 1574, 1497, 1384, 1297, 1259, 1117 cm^−1^; ^1^H and ^13^C NMR, see [Table 3](#marinedrugs-14-00134-t003){ref-type="table"}; HRESIMS *m/z* 221.0819 \[M + H\]^+^ (calculated for C~12~H~13~O~4~, 221.0814).

### 3.2.5. Quadricinctone B: 6-Hydroxy-2,2-dimethyl-8-(methylsulfinyl)-2,3-dihydro-4*H*-chromen-4-one (**4b**) {#sec3dot2dot5-marinedrugs-14-00134}

White crystals; mp 227--228 °C (CHCl~3~/Me~2~CO); ${\lbrack\alpha\rbrack}_{D}^{20}$ +30° (*c* 0.03, MeOH); UV (MeOH) λ~max~ (log ε) 205 (4.27), 234 (4.22), 358 (3.64) nm; IR (KBr) υ~max~ 3442, 2975, 2922, 1690, 1622, 1484, 1441, 1417, 1326, 1251, 1177 cm^−1^; ^1^H and ^13^C NMR, see [Table 4](#marinedrugs-14-00134-t004){ref-type="table"}; HRESIMS *m/z* 255.0694 \[M + H\]^+^ (calculated for C~12~H~15~O~4~S, 255.0691).

### 3.2.6. Quadricinctone C: 3,6,8-Trihydroxy-3-(hydroxymethyl)-4,5-dimethyl-3,4-dihydro-1*H*-isochromen-1-one (**5**) {#sec3dot2dot6-marinedrugs-14-00134}

White crystals; mp 223--224 °C (CHCl~3~/Me~2~CO); ${\lbrack\alpha\rbrack}_{D}^{20}$ +64° (*c* 0.06, MeOH); UV (MeOH) λ~max~ (log ε) 214 (4.23), 271 (3.96), 312 (3.70) nm; IR (KBr) υ~max~ 3439, 3006, 2976, 2360, 2342, 1660, 1644, 1600, 1494, 1472, 1448, 1385, 1157 cm^−1^; ^1^H and ^13^C NMR, see [Table 5](#marinedrugs-14-00134-t005){ref-type="table"}; HRESIMS *m/z* 255.0875 \[M + H\]^+^ (calculated for C~12~H~15~O~6~, 255.0869).

### 3.2.7. Quadricinctafuran A: (2*R*)-(2-Hydroxypropan-2-yl)-2,3-dihydro-1-benzofuran-5-carboxylic acid (**6a**) {#sec3dot2dot7-marinedrugs-14-00134}

White crystals; mp 149--150 °C (CHCl~3~/Me~2~CO); ${\lbrack\alpha\rbrack}_{D}^{20}$ +74° (*c* 0.03, MeOH); UV (MeOH) λ~max~ (log ε) 203 (3.40), 254 (3.49) nm; IR (KBr) υ~max~ 3417, 2920, 1681, 1634, 1491, 1261 cm^−1^; ^1^H and ^13^C NMR, see [Table 6](#marinedrugs-14-00134-t006){ref-type="table"}; HRESIMS *m/z* 223.9067\[M + H\]^+^ (calculated for C~12~H~15~O~4~, 223.0970).

### 3.2.8. Quadricinctafuran B: (2R)-2-(1,2-Hihydroxypropan-2-yl)-2,3-dihydro-1-benzofuran-5-carboxylic acid (**6b**) {#sec3dot2dot8-marinedrugs-14-00134}

White solid; mp 209--210 °C (CHCl~3~/Me~2~CO); ${\lbrack\alpha\rbrack}_{D}^{20}$ +20° (*c* 0.05, MeOH); UV (MeOH) λ~max~ (log ε) 205 (4.27), 261 (4.03) nm; IR (KBr) υ~max~ 3328, 2984, 2941, 1673, 1610, 1599, 1495, 1362, 1290, 1247 cm^−1^; ^1^H and ^13^C NMR, see [Table 6](#marinedrugs-14-00134-t006){ref-type="table"}; HRESIMS *m/z* 239.0919\[M + H\]^+^ (calculated for C~12~H~15~O~5~, 239.0919).

### 3.2.9. Quadricinctone D: 7-Hydroxy-3-(hydroxymethyl)-3-methyl-3,4-dihydro-2-benzoxepine-1, 5-dione (**7**) {#sec3dot2dot9-marinedrugs-14-00134}

White crystals; mp 196--197 °C (CHCl~3~/Me~2~CO); ${\lbrack\alpha\rbrack}_{D}^{20}$ +19° (*c* 0.05, MeOH); UV (MeOH) λ~max~ (log ε) 232 (4.21), 254 (3.84) nm; IR (KBr) υ~max~ 3404, 2934, 2360, 2341, 1708, 1670, 1614, 1492, 1466, 1250 cm^−1^; ^1^H and ^13^C NMR, see [Table 7](#marinedrugs-14-00134-t007){ref-type="table"}; HRESIMS *m/z* 237.0792 \[M + H\]^+^ (calculated for C~12~H~15~O~5~, 237.0763).

3.3. X-Ray Crystal Structure of Compounds **1**, **2a**, **4b**, **5**, **6a** and **7** {#sec3dot3-marinedrugs-14-00134}
----------------------------------------------------------------------------------------

Diffraction data were collected at 293 K with a Gemini PX Ultra equipped with CuK~α~ radiation (λ = 1.54184 Å). The structures were solved by direct methods using SHELXS-97 and refined with SHELXL-97 \[[@B23-marinedrugs-14-00134]\]. Carbon, oxygen and sulphur atoms were refined anisotropically. Hydrogen atoms were either placed at their idealized positions using appropriate HFIX instructions in SHELXL and included in subsequent refinement cycles or were directly found from difference Fourier maps and were refined freely with isotropic displacement parameters. Full details of the data collection and refinement and tables of atomic coordinates, bond lengths and angles and torsion angles have been deposited with the Cambridge Crystallographic Data Centre.

Quadricinctone A (**1**): Crystals were triclinic, space group P1, cell volume 663.27(7) Å^3^ and unit cell dimensions *a* = 7.3973(5)Å, *b* =8.4830(6)Å and *c* = 11.2438(6) Å and angles *α* = 107.541(5)°, *β* = 92.005(5)° and *γ* = 98.365(6)° (uncertainties in parentheses). The refinement converged to *R* (all data) = 3.68% and *wR*~2~ (all data) = 9.54%. The absolute structure was established with confidence (flack *x* parameter 0.028(18)). CCDC 1465376.

Quadricinctapyran A (**2a**): Crystals were orthorhombic, space group P*bcn*, cell volume 2189.45(9) Å^3^ and unit cell dimensions *a* = 21.3981(5)Å, *b* = 14.5017(3)Å and *c* = 7.05561(18)Å. The refinement converged to *R* (all data) = 15.06% and *wR*~2~ (all data) = 40.39%. CCDC 1468869.

Quadricinctone B (**4b**): Crystals were orthorhombic, space group I*ba2*, cell volume 2469.66(11) Å^3^ and unit cell dimensions *a* = 8.52510(19)Å, *b* = 30.2340(7)Å and *c* = 9.5817(3)Å. The refinement converged to *R* (all data) = 5.90% and *wR*~2~ (all data) = 15.62%. The absolute structure was established with confidence (flack *x* parameter −0.04(4)). CCDC 1468868.

Quadricinctone C (**5**): Crystals were monoclinic, space group P*2~1~*, cell volume 1116.25(5) Å^3^ and unit cell dimensions *a* = 12.1131(3)Å, *b* = 7.0501(2)Å and *c* = 13.2091(3)Å and *β* = 98.291(2)°. The refinement converged to *R* (all data) = 6.85% and *wR*~2~ (all data) = 17.04%. CCDC 1468170.

Quadricinctafuran A (**6a**): Crystals were monoclinic, space group P*2~1~/n*, cell volume 1066.67(10)Å^3^ and unit cell dimensions *a* = 11.6064(7)Å, *b* = 5.9593(2)Å and *c* = 15.8588(8)Å and *β* = 103.481(6)°. The refinement converged to *R* (all data) = 11.08% and *wR*~2~ (all data) = 24.01%. CCDC 1468171.

Quadricinctone D (**7**): Crystals were orthorhombic, space group P*ca2~1~*, cell volume 1081.35(13) Å^3^ and unit cell dimensions *a* = 19.5607(13)Å, *b* = 7.4646(5)Å and *c* = 7.4058(5)Å. The refinement converged to *R* (all data) = 3.81% and *wR*~2~ (all data) = 8.57%. CCDC 1468166.

3.4. Molecular Mechanics Conformation Analysis of **3** and **7** {#sec3dot4-marinedrugs-14-00134}
-----------------------------------------------------------------

Molecular simulations for Structures **3** and **7** were carried out in ChemBio3D Ultra 14 (Perkin-Elmer). Molecular mechanics energy minimizations used the MM2 and MMFF force fields with the ChemBio3D most recent default parameters and implementation, adequate for small to medium carbon-based models. Ab initio MP2/6-311G and semi-empirical PM3 molecular modelling was done using CS GAMESS interfaced by ChemBio3D. The conformational search was done by stochastic, dihedral driver and molecular dynamics methods. Around 60 conformations were stochastically created and then minimized using the PM3, MMFF and PM3 methods. The resulting models were then grouped under the resultant two seven-membered ring conformations (exemplified in [Figure 8](#marinedrugs-14-00134-f008){ref-type="fig"} for **3**). A minimal energy for each model set was found by driving by 360° the dihedral angles of the single bonds that attach substituent groups to the rings. Molecular dynamics runs were also applied to the models to confirm the convergence to a minimal energy conformation for each model set.

4. Conclusions {#sec4-marinedrugs-14-00134}
==============

Although Ozoe et al. had first reported the isolation of an isocoumarin derivative from the culture of the fungus *N. quadricincta* strain PF1223, using a GABA receptor ligand as a screening target, the source of the fungus was not revealed. Therefore, this is the first report on the secondary metabolites of the culture of a marine-derived *N. quadricincta* (KUFA 0081). Among the nine new isolated compounds, two are polyketide derivatives, and seven are benzoic acid derivatives. The isolation of these structurally-unique, but related, metabolites from this fungus has allowed us to propose the biosynthetic pathways leading to these metabolites. Interestingly, the unprecedented structure of quadricinctone B (**4b**), which possesses a methyl sulfinyl group in the benzopyran nucleus, reflects the capacity of this marine-derived strain to introduce sulphur into the aromatic ring. Therefore, this marine strain of *N. quadricincta* (KUFA 0081) can have potential for biotechnological transformation. Even though the isolated metabolites did not exhibit either antifungal/antibacterial activities or growth inhibitory activity against the three cancer cell lines in our assay protocols, it does not mean that they are devoid of other interesting biological activities. Therefore, it is necessary to investigate these metabolites in other target-based assay protocols.
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The supplementary materials are available online at [www.mdpi.com/1660-3397/14/7/134/s1](www.mdpi.com/1660-3397/14/7/134/s1).
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Secondary metabolites of *N. quadricincta* KUFA0081.
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###### 

^1^H and ^13^C NMR (CDCl~3~, 300.13 MHz and 75.4 MHz), HMBC and NOESY assignments for **1**.

  Position   δ~C~, type    δ~H~, (*J* in Hz)   HMBC               NOESY
  ---------- ------------- ------------------- ------------------ ------------
  1          168.2, CO     \-                                     
  3          88.8, C       \-                                     
  3a         152.8, C      \-                                     
  4          111.7, C      \-                                     
  5          164.6, C      \-                                     
  6          94.5, CH      6.41, s             C-1, 4, 5, 7, 7a   OMe-5, 7
  7          158.3, C      \-                                     
  7a         105.3, C      \-                                     
  8          11.2, CH~3~   2.12, s             C-3a, 4, 5, 7      H-9, 10
  9          21.5, CH~3~   1.76, s             C-3, 3a, 10        H-8, 9
  10         70.8, CH      4.22, d (6.4)       C-11               H-8, 9, 10
  11         17.8, CH~3~   0.87, d (6.4)       C-3, 10            H-10
  OMe-5      56.1, CH~3~   3.92, s             C-5                H-6
  OMe-7      56.0, CH~3~   3.97, s             C-7                H-6
  OH-10      \-            2.15, br            \-                 H-11
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###### 

^1^H and ^13^C NMR (DMSO, 300.13 MHz and 75.4 MHz) for **2a** and **2b**.

  Position   2a                                  2b                                                                           
  ---------- ------------- --------------------- -------- ------------------- -- ------------- --------------------- -------- ----------------
  2          80.5, C       \-                                                    78.5, C       \-                             
  3          128.6, CH     5.74, d (10.0)        H-4      C-2, 4a, 5, 9, 10      126.2, CH     5.59, d (10.0)        H-4      C-2, 4a, 10
  4          122.8, CH     6.56, d (10.0)        H-3      C-2, 5, 8a             124.3, CH     6.51, d (10.0)        H-3      C-2, 5, 8a
  4a         120.5, C      \-                                                    120.2, C      \-                             
  5          127.9, CH     7.65, d (2.1)         H-7      C-4, 8a, 11            128.9, CH     7.75, d (2.1)         H-7      C-4, 7, 8a, 11
  6          123.0, C      \-                                                    122.0, C      \-                             
  7          139.8, CH     7.69, dd (8.4, 2.1)   H-5, 8   C-5, 8a, 11            132.2, CH     7.90, dd (8.5, 2.1)   H-5, 8   C-5, 8a, 11
  8          115.7, CH     6.79, d (8.4)         H-7      C-4a, 6, 8a            116.1, CH     6.83, d (8.5)         H-7      C-4a, 6, 8a
  8a         156.8, C      \-                                                    157.8, C      \-                             
  9          23.3, CH~3~   1.31, s               \-       C-2, 3, 10             24.0, CH~3~   1.48, s               \-       C-2, 3, 10
  10         67.1, CH~2~   3.45, s               \-       C-2, 3, 9              68.8, CH~2~   4.13, d (11.7)        H-10     C-2, 3, 9
                                                                                               4.24, d (11.7)        H-10     C-2, 3, 9
  11         167.0, CO     \-                                                    171.7, CO     \-                             
  OH-10      \-            5.07, br              \-                              \-            \-                             
  OH-11      \-            12.59, br             \-                              \-            12.79, br             \-       
  OAc        \-                                                                  170.8, CO     \-                             
                                                                                 20.7, CH~3~   1.98, s               \-       CO (Ac)
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###### 

^1^H and ^13^C NMR (DMSO, 300.13 MHz and 75.4 MHz) and HMBC assignment for **3**.

  Position      δ~C~, type    δ~H~, (*J* in Hz)      COSY     HMBC             NOESY
  ------------- ------------- ---------------------- -------- ---------------- ------------------------
  2α            77.0, CH~2~   3.84, d (11.1)         H-2β     C-3, 4, 9a, 11   H-2β, 4 (w), 11 (w)
  β                           4.02, dd (11.1, 1.6)   H-2α     C-3, 4, 9a, 11   H-2α, 4 (w), 11 (str)
  3             70.7, C       \-                                               
  4             139.5, CH     5.95, dd (12.0, 1.2)   H-5      C-2, 5a          H-2α (w), 5, 9 (w), 11
  5             123.5, CH     6.31, d (12.0)         H-4      C-3, 5a, 6, 9a   H-4, 6 (str)
  5a            125.0, C      \-                                               
  6             134.5, CH     7.89, d (2.1)          H-8      C-5, 8, 9a, 10   H-5
  7             125.3, C      \-                                               
  8             129.8, CH     7.74, dd (8.4, 2.1)    H-6, 9   C-6, 9a          H-9
  9             119.8, CH     7.05, d (8.4)          H-8      C-5a, 7, 9a      H-8
  9a            161.2, C      \-                                               
  10            166.7, C      \-                                               
  11            26.1, CH~3~   1.26, s                \-       C-2, 3, 4        H-2α (w), 2β (str)
  OH-3          \-            3.39, br               \-                        H-4, 11
  CO[OH]{.ul}   \-            12.79, br              \-                        
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###### 

^1^H and ^13^C NMR (DMSO, 300.13 MHz and 75.4 MHz) and HMBC assignment for **4b**.

  Position   δ~C~, type    δ~H~, (*J* in Hz)   COSY   HMBC
  ---------- ------------- ------------------- ------ ---------------
  2          80.9, C       \-                         
  3          48.0, CH~2~   2.80, d (16.6)      H-3    C-2, 4, 9, 10
                           2.85, d (16.6)      H-3    C-2, 4, 9, 10
  4          191.2, CO     \-                         
  4a         120.8, C      \-                         
  5          112.4, CH     7.17, d (3.1)       H-7    C-4, 6, 7, 8a
  6          151.6, C      \-                         
  7          118.7, CH     7.35, d (3.1)       H-5    C-5, 6, 8, 8a
  8          135.7, C      \-                         
  8a         147.4, C      \-                         
  9          26.1, CH~3~   1.39, s             \-     C-2, 3, 10
  10         25.7, CH~3~   1.38, s             \-     C-2, 3, 9
  11         40.8, CH~3~   2.77, s             \-     C-8
  OH-6       \-            9.85, s                    C-5, 6, 7
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###### 

^1^H and ^13^C NMR (DMSO, 300.13 MHz and 75.4 MHz) and HMBC assignment for **5**.

  Position   δ~C~, type    δ~H~, (*J* in Hz)   COSY      HMBC
  ---------- ------------- ------------------- --------- ----------------------
  1          168.8, C      \-                            
  3          104.8, C      \-                            
  4          34.9, CH      3.26, m             H~3~-10   
  4a         144.6, C      \-                            
  5          113.5, C      \-                            
  6          162.9, C      \-                            
  7          99.9, CH      6.27, s             \-        C-1 (w), 5, 6, 8, 8a
  8          161.3, C      \-                            
  8a         98.9, C       \-                            
  9          63.7, CH~2~   3.65, brd (16.6)    OH-9      
  10         16.3, CH~3~   1.06, d (7.2)       H-4       C-3, 4, 4a
  11         9.8, CH~3~    1.98, s             \-        C-4a, 5, 6
  OH-3       \-            7.07, br            \-        
  OH-5       \-            10.62, br           \-        
  OH-8       \-            11.24, s            \-        C-7, 8, 8a
  OH-9       \-            5.26, br            \-        
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###### 

^1^H and ^13^C NMR (DMSO, 300.13 MHz and 75.4 MHz) and HMBC assignment for **6a** and **6b**.

  Position   6a                                  6b                                                                         
  ---------- ------------- --------------------- -------- ----------------- -- ------------- --------------------- -------- -------------
  2          90.2, CH      4.64, t (8.9)         H-3      C-1′, 2′, 3′         86.5, CH      4.83, dd (9.7, 8.1)   H-3      
  3          29.3, CH~2~   3.17, d (8.9)         H-2      C-1′, 2, 3a, 7a      28.7, CH~2~   3.19, m               H-2      C-1′, 3a
  3a         128.2, C      \-                                                  128.4, C      \-                             
  4          126.4, CH     7.75, d (1.8)         H-6      C-6, 7a, 8           126.4, CH     7.76, d (1.8)         H-6      C-3, 6, 7a
  5          122.6, C      \-                                                  122.6, C      \-                             
  6          130.4, CH     7.72, dd (8.3, 1.8)   H-4, 7   C-4, 7a, 8           130.8, CH     7.71, dd (8.3, 1.8)   H-4, 7   C-4, 7a, 8
  7          108.4, CH     6.80, d (8.3)         H-6      C-3a, 5, 7a          108.4, CH     6.79, d (8.3)         H-6      C-3a, 5, 7a
  7a         163.7, C      \-                                                  163.6, C      \-                             
  8          167.2, C      \-                                                  167.2, C      \-                             
  1′         70.0, C       \-                                                  72.5, C       \-                             
  2′         24.9, CH~3~   1.14, s               \-       C-1′, 2, 3′          66.7, CH~2~   3.33, s               \-       C-1′, 2, 3′
  3′         25.9, CH~3~   1.13, s               \-       C-1′, 2, 2′          20.0, CH~3~   1.09, s                        C-1′, 2, 2′
  OH-8       \-            12.49, br             \-                            \-            12.47, br             \-       
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###### 

^1^H and ^13^C NMR (CDCl~3~, 300.13 MHz and 75.47 MHz) and HMBC assignment for **7**.

  Position   δ~C~, Type    δ~H~, (*J* in Hz)      COSY     HMBC             NOESY
  ---------- ------------- ---------------------- -------- ---------------- ---------------------------------
  2          80.3, C       \-                                               
  3α         434, CH~2~    2.74, d (16.7)         H-3      C-2, 4, 10, 11   H~3~-11 (str)
  β                        3.00, d (16.7)         H-3      C-2, 4, 10, 11   H~3~-11 (w)
  4          191.1, CO     \-                                               
  4a         123.0, C      \-                                               
  5          127.5, CH     8.26, d (2.3)          H-7      C-4, 7, 8a       
  6          119.6, C      \-                                               
  7          136.4, CH     8.04, dd (8.7, 2.3)    H-5, 8   C-5, 8a          
  8          118.5, CH     7.07, d (8.7)          H-7      C-4a, 6, 8       
  8a         162.9, C      \-                                               
  9          21.2, CH~3~   1.30, s                \-       C-2, 3, 10       H-3α (str), H3β (w), H-5, 8 (w)
  10         66.8, CH~2~   3.49, dd (11.6, 4.5)   OH-10                     
                           3.59, dd (11.6, 4.2)                             
  11         166.4, CO     \-                                               
  OH-10      \-            5.26, brt (5.4)        \-                        
  OH-11      \-            12.69, br              \-                        
